跳至主要内容
临床试验/JPRN-UMIN000013018
JPRN-UMIN000013018已完成未知

Sivelestat Sodium Hydrate Treatment for Patients with Kawasaki Disease refractory to initial intravenous immunoglobulin therapy - Sivelestat Sodium Hydrate Treatment for severe Kawasaki Disease

Department of Pediatrics, Chiba University Hospital0 个研究点目标入组 45 人开始时间: 2014年2月1日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
45

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
ot applicable 至 20years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • We excluded patients who become afebrile within 48 hours after beginning of initial IVIG therapy but become febrile again after day 10 of illness, those with concomitant severe medical disorders (eg, immunodeficiency, chromosomal anomalies, congenital heart diseases, metabolic diseases, nephritis, collagen diseases), those with suspected infectious disease, including sepsis, septic meningitis, peritonitis, bacterial pneumonia, varicella, and influenza, those with allergy to some drugs and substances and those who have already been enrolled in other clinical trials.

研究者

发起方
Department of Pediatrics, Chiba University Hospital

相似试验

Sivelestat Sodium Hydrate Treatment for Patients... | 临床试验